Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2013 (2013), Article ID 952321, 6 pages
http://dx.doi.org/10.1155/2013/952321
Research Article

Future of Management of Multiple Sclerosis in the Middle East: A Consensus View from Specialists in Ten Countries

1King Abdullah International Medical Research Center, King Saud Ben Abdulaziz University for Health Sciences, National Guard Health Affairs, P.O. Box 22490, Riyadh 11426, Saudi Arabia
2Prince Mohammed Ben Abdulaziz Hospital, Ministry of Health, Riyadh 1176, Saudi Arabia
3Division of Neurology, Amiri Hospital Kuwait, P.O. Box 1661, 73767 Qurtoba, Kuwait
4Division of Neurology, Dasman Diabetes Institute, 15462 Dasman, Kuwait
5Clinical Neurosciences Department, Salmaniya Medical Complex, 20525 Manama, Bahrain
6Department of Neurosciences, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia
7Department of Internal Medicine, Neurology Section, Arab Medical Center and Khalidi Hospital, P.O. Box 925209, Amman 11190, Jordan
8Department of Neurology (Medicine), Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar
9Merck Serono Intercontinental Region, Dubai 22730, UAE
10Department of Neurology, Damascus Hospital, P.O. Box 10053, Damascus, Syria
11MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran 1136746911, Iran
12Division of Neurology, Department of Medicine, Tawam Hospital, P.O. Box 15258, Al Ain, UAE
13Neurology Section, King Khalid University Hospital, College of Medicine, King Saud University, Riyadh 11691, Saudi Arabia
14American University of Beirut Medical Center, Multiple Sclerosis Center, P.O. Box 11-0236, Beirut, Lebanon
15Neurologische Klinik Bamberg, 96049 Bamberg, Germany

Received 6 September 2013; Revised 28 October 2013; Accepted 29 October 2013

Academic Editor: Wolfgang Bruck

Copyright © 2013 Mohammed Aljumah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Multiple Sclerosis International Federation, “Atlas of MS,” 2013, http://www.msif.org/en/about_msif/what_we_do/atlas_of_ms.
  2. P. Rieckmann, A. Boyko, D. Centonze et al., “Future MS care: a consensus statement of the MS in the 21st Century Steering Group,” Journal of Neurology, vol. 260, no. 2, pp. 462–469, 2013. View at Google Scholar
  3. A. H. Maghzi, H. Ghazavi, M. Ahsan et al., “Increasing female preponderance of multiple sclerosis in Isfahan, Iran: a population-based study,” Multiple Sclerosis, vol. 16, no. 3, pp. 359–361, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Bohlega, J. Inshasi, A. R. Al Tahan, A. B. Madani, H. Qahtani, and P. Rieckmann, “Multiple sclerosis in the Arabian Gulf countries: a consensus statement,” Journal of Neurology, 2013. View at Google Scholar
  5. M. Etemadifar and S. H. Abtahi, “Multiple sclerosis in Isfahan, Iran: past, present and future,” International Journal of Preventive Medicine, vol. 3, no. 5, pp. 301–302, 2012. View at Google Scholar
  6. J. Inshasi and M. Thakre, “Prevalence of multiple sclerosis in Dubai, United Arab Emirates,” International Journal of Neuroscience, vol. 121, no. 7, pp. 393–398, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Al-Hashel, A. D. Besterman, and C. Wolfson, “The prevalence of multiple sclerosis in the middle east,” Neuroepidemiology, vol. 31, no. 2, pp. 129–137, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Deleu, D. Mir, A. Al Tabouki et al., “Prevalence, demographics and clinical characteristics of multiple sclerosis in Qatar,” Multiple Sclerosis, vol. 19, no. 6, pp. 816–819, 2013. View at Google Scholar
  9. C. E. Markowitz, “The current landscape and unmet needs in multiple sclerosis,” The American Journal of Managed Care, vol. 16, no. 8, supplement, pp. S211–S218, 2010. View at Google Scholar · View at Scopus
  10. R. Gold, J. S. Wolinsky, M. P. Amato, and G. Comi, “Evolving expectations around early management of multiple sclerosis,” Therapeutic Advances in Neurological Disorders, vol. 3, no. 6, pp. 351–367, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Noyes, A. Bajorska, A. Chappel et al., “Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study,” Neurology, vol. 77, no. 4, pp. 355–363, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. National institute for Health and Clinical Excellence, “Multiple sclerosis: CG 8. Management of multiple sclerosis in primary and secondary care,” 2013, http://publications.nice.org.uk/multiple-sclerosis-cg8.
  13. A. Jain, “NICE recommends faster, easier access to care for MS patients,” Bitish Medical Journal, vol. 327, no. 7426, article 1247, 2003. View at Google Scholar · View at Scopus
  14. B. I. Yamout, M. Dahdaleh, M. A. A. Jumah et al., “Adherence to disease-modifying drugs in patients with multiple sclerosis: a consensus statement from the middle east MS advisory group,” International Journal of Neuroscience, vol. 120, no. 4, pp. 273–279, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Riñon, M. Buch, D. Holley, and E. Verdun, “The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis,” Patient Preference and Adherence, vol. 5, pp. 629–643, 2011. View at Google Scholar
  16. R. L. Askew, D. Amtmann, V. G. Weir, and K. Johnson, “Exploring unmet needs in multiple sclerosis: who needs what?” International Journal of MS Care, vol. 14, supplement 2, p. 86, 2012. View at Google Scholar
  17. J. Wollin, H. Dale, N. Spenser, and N. Walsh, “What people with newly diagnosed MS (and their families and friends) need to know,” International Journal of MS Care, vol. 2, no. 3, pp. 29–39, 2000. View at Google Scholar
  18. I. Juraskova, J. Chapman, P. N. Butow et al., “Challenges, needs, rewards, and psychological well-being of multiple sclerosis support-group facilitators,” International Journal of MS Care, vol. 10, no. 3, pp. 85–93, 2008. View at Google Scholar
  19. M. Plow, M. Finlayson, and C. Cho, “Correlates of nutritional behavior in individuals with multiple sclerosis,” Disability and Health Journal, vol. 5, no. 4, pp. 284–291, 2012. View at Google Scholar
  20. M. Edlin and P. Sonnenreich, “Trends in managing multiple sclerosis,” P & T, vol. 33, no. 10, pp. 611–614, 2008. View at Google Scholar · View at Scopus
  21. P. McCrone, M. Heslin, M. Knapp, P. Bull, and A. Thompson, “Multiple sclerosis in the UK: service use, costs, quality of life and disability,” PharmacoEconomics, vol. 26, no. 10, pp. 847–860, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Ashtari and M. R. Savoj, “Effects of low dose Methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: a randomized controlled trial,” Journal of Research in Medical Sciences, vol. 16, no. 4, pp. 457–462, 2011. View at Google Scholar · View at Scopus
  23. M. Etemadifar, M. Janghorbani, and V. Shaygannejad, “Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis,” Acta Neurologica Scandinavica, vol. 113, no. 5, pp. 283–287, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Mazdeh, S. Afzali, and M. R. Jaafari, “The therapeutic effect of avonex, rebif and betaferon on EDSS and relapse in multiple sclerosis: a comparative study,” Acta Medica Iranica, vol. 48, no. 2, pp. 83–88, 2010. View at Google Scholar · View at Scopus
  25. M. Etemadifar, M. Janghorbani, and V. Shaygannejad, “Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis,” Journal of Neurology, vol. 254, no. 12, pp. 1723–1728, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Nafissi, A. Azimi, A. Amini-Harandi, S. Salami, M. A. Shahkarami, and R. Heshmat, “Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial,” Clinical Neurology and Neurosurgery, vol. 114, no. 7, pp. 986–989, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Pakdaman, M. A. Sahraian, A. Fallah et al., “Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event,” Acta Neurologica Scandinavica, vol. 115, no. 6, pp. 429–431, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. M. R. Motamed, N. Najimi, and S.-M. Fereshtehnejad, “The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis,” Clinical Neurology and Neurosurgery, vol. 109, no. 4, pp. 344–349, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. I. Kister, E. Chamot, J. H. Bacon, G. Cutter, and J. Herbert, “Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium,” Multiple Sclerosis, vol. 17, no. 6, pp. 725–733, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. D. S. Goodin, A. T. Reder, and G. C. Ebers, “Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial,” Neurology, vol. 78, no. 17, pp. 1315–1322, 2012. View at Google Scholar
  31. L. Ottoboni, B. T. Keenan, P. Tamayo et al., “An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity,” Science Translational Medicine, vol. 4, no. 153, p. 153ra131, 2012. View at Google Scholar
  32. National Institutes of Health, “Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC),” 2013, http://report.nih.gov/categorical_spending.aspx.
  33. W. H. Stuart, “Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management,” Journal of Managed Care Pharmacy, vol. 10, no. 3, pp. S19–S25, 2004. View at Google Scholar · View at Scopus
  34. N. S. Roskell, E. A. Zimovetz, C. E. Rycroft, B. J. EckertJ, and D. A. Tyas, “Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod,” Current Medical Research and Opinion, vol. 28, no. 5, pp. 767–780, 2012. View at Google Scholar
  35. L. La Mantia, L. Vacchi, C. Di Pietrantonj et al., “Interferon beta for secondary progressive multiple sclerosis,” Cochrane Database of Systematic Reviews, vol. 1, Article ID CD005181, 2012. View at Google Scholar
  36. H. Tedeholm, J. Lycke, B. Skoog et al., “Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs,” Multiple Sclerosis, vol. 19, no. 6, pp. 765–774, 2013. View at Google Scholar
  37. G. L. Plosker, “Interferon-β-1b: a review of its use in multiple sclerosis,” CNS Drugs, vol. 25, no. 1, pp. 67–88, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Girouard and N. Soucy, “Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents,” Patient Preference and Adherence, vol. 5, pp. 101–108, 2011. View at Google Scholar
  39. K. K. Daugherty, J. S. Butler, M. Mattingly, and M. Ryan, “Factors leading patients to discontinue multiple sclerosis therapies,” Journal of the American Pharmacists Association, vol. 45, no. 3, pp. 371–375, 2005. View at Google Scholar · View at Scopus